Treatment
Durvalumab clinical trials
We’re tracking 167 recruiting studies that include Durvalumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06890598RecruitingPhase 3
Study of olomorasib for KRAS G12C-mutant lung cancer
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
Huntsville, AlabamaAges 18 years+ - NCT06890273Recruiting
Study of durvalumab and olaparib for endometrial cancer
This study looks at how well two drugs, durvalumab and olaparib, work together after initial chemotherapy for advanced or recurrent endometrial cancer. It may help patients who have not had many treatment options before.
AmbergAges 18–130 - NCT06858735RecruitingPhase 2
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2 trial evaluating systemic therapy ± liver-directed RT for advanced intrahepatic cholangiocarcinoma, with broad eligibility for patients who have received at least 4 cycles of gem/cis/durvalumab.
Houston, TexasAges 18 years+ - NCT06824363RecruitingEarly Phase 1
Intra-tumor injection study for stomach and esophagus cancer with ARID1a mutation
This trial tests a new approach where immune cells are injected directly into the tumor in people with a specific genetic change (ARID1a mutation) in their stomach or esophagus cancer. It aims to see if this treatment can help when used before any other cancer therapy.
Orange, CaliforniaAges 18 years+ - NCT06810609RecruitingPhase 2
Immunochemotherapy, surgery, and durvalumab for stage III lung cancer
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Freiburg im Breisgau, Baden-WurttembergAges 18–74 - NCT06796114Recruiting
Biomarkers in advanced liver cancer treated with tremelimumab/durvalumab
This study is looking for people with advanced liver cancer (hepatocellular carcinoma) who have not yet had systemic treatment. Participants will receive a combination of two immunotherapy drugs: tremelimumab and durvalumab (the STRIDE regimen). The goal is to find biomarkers that can predict how well the cancer responds to this treatment.
BesançonAges 18 years+ - NCT06780137RecruitingPhase 1/Phase 2
Gocatamig plus ifinatamab deruxtecan for advanced small cell lung cancer
This study tests two new drugs (gocatamig and ifinatamab deruxtecan) for people whose small cell lung cancer has spread or come back after standard chemotherapy. It aims to see if the combination works better than current options.
Aurora, ColoradoAges 18 years+ - NCT06769126RecruitingPhase 2
Personalized treatment study for extensive stage small cell lung cancer
This study uses biomarker tests on your tumor to find a personalized treatment after initial chemotherapy. You will be assigned to one of four treatment groups based on your biomarker results.
Loma Linda, CaliforniaAges 18 years+ - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT06680739RecruitingPhase 2
Study of immunotherapy for colorectal and endometrial cancer
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
BarcelonaAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
La Jolla, CaliforniaAges 18 years+ - NCT06634199Recruiting
Immune response after chemoradiation and immunotherapy for stage III lung cancer
This study looks at how the body’s immune system responds in people with stage III lung cancer (not removable by surgery) who first get chemotherapy and radiation and then receive the immunotherapy drug durvalumab for one year. It aims to learn more about the immune response and why the treatment works better for some people.
Ferrol, A CoruñaAges 18 years+ - NCT06630130RecruitingPhase 2
Surgery and drug therapy for advanced stomach cancer
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
SeoulAges 19 years+ - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Stanford, CaliforniaAges 18 years+ - NCT06546969RecruitingPhase 1
Combination therapy for advanced bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
Baltimore, MarylandAges 21 years+ - NCT06498635RecruitingPhase 3
Immunotherapy after surgery for lung cancer with no remaining cancer
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
Jonesboro, ArkansasAges 18 years+ - NCT06484491Recruiting
Higher-dose proton therapy for stage III lung cancer
This trial tests whether giving a higher dose of a special, precise form of radiation (proton therapy) to the main tumor can improve outcomes for people with stage III lung cancer who are already scheduled for chemoradiation and immunotherapy. It may help by targeting the tumor more effectively while protecting nearby organs.
GroningenAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06467357RecruitingPhase 3
New drug combo for advanced bile duct cancer with HER2
This study tests a new combination of drugs for advanced bile duct cancer that has not been treated yet and shows a protein called HER2. It compares the new combination to the standard treatment to see if it works better or has fewer side effects.
Scottsdale, ArizonaAges 18–99 - NCT06375915RecruitingPhase 2
Radioembolization and targeted therapy for unresectable bile duct cancer
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
BergamoAges 18–80 - NCT06302426RecruitingPhase 1
Testing INI-4001 for advanced solid tumors
This trial tests a new drug, INI-4001, for people with advanced solid tumors that have spread or can't be removed. It aims to see if the drug is safe and effective.
Albury, New South WalesAges 18 years+ - NCT06290505RecruitingPhase 2
Palliative therapy for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (durvalumab) for esophageal cancer that has spread to a few other places in the body or is too advanced for surgery. It aims to see if this combination helps with swallowing difficulties and slows the cancer's growth.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Duarte, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Durvalumab?
- Yes. Clin2 currently lists 167 recruiting studies that include Durvalumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Durvalumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Durvalumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Durvalumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.